Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The accumulation of DNA and RNA oxidative damage is observed in cortical and hippocampal neurons from Alzheimer's disease (AD) brains at early stages of pathology. We recently reported that Tau is a key nuclear player in the protection of neuronal nucleic acid integrity in vivo under physiological conditions and hyperthermia, a strong inducer of oxidative stress. In a mouse model of tauopathy (THY-Tau22), we demonstrate that hyperthermia selectively induces nucleic acid oxidative damage and nucleic acid strand breaks in the nucleus and cytoplasm of hippocampal neurons that display early Tau phosphorylation but no Tau fibrils. Nucleic acid-damaged neurons were exclusively immunoreactive for prefibrillar Tau oligomers. A similar association between prefibrillar Tau oligomers and nucleic acid oxidative damage was observed in AD brains. Pretreatment with Methylene Blue (MB), a Tau aggregation inhibitor and a redox cycler, reduced hyperthermia-induced Tau oligomerization as well as nucleic acid damage. This study clearly highlights the existence of an early and critical time frame for hyperthermia-induced Tau oligomerization, which most likely occurs through increased oxidative stress, and nucleic acid vulnerability during the progression of Tau pathology. These results suggest that at early stages of AD, Tau oligomerization triggers the loss of the nucleic acid protective function of monomeric Tau. This study highlights the existence of a short therapeutic window in which to prevent the formation of pathological forms of Tau and their harmful consequences on nucleic acid integrity during the progression of Tau pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885
Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., & Kayed, R. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-39 · Cited by 633
Self-citationKampers, T., Friedhoff, P., Biernat, J., Mandelkow, E.-M., & Mandelkow, E. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01386-5 · Cited by 548
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease
Lasagna‐Reeves, C. A., Castillo‐Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., & Kayed, R. (2012) · The FASEB Journal · doi:10.1096/fj.11-199851 · Cited by 527
Self-citationNuclear Tau, a Key Player in Neuronal DNA Protection
Sultan, A., Nesslany, F., Violet, M., Bégard, S., Loyens, A., Talahari, S., Mansuroglu, Z., Marzin, D., Sergeant, N., Humez, S., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.199976 · Cited by 421 · cited 1×
“…role in microtubule assembly and stabilization, Tau is an essential nuclear player in the protection of neuronal genomic DNA integrity under hyperthermic stress (HS), which is known to generate abundant reactive oxygen species (ROS), primarily in neuronal cultures (Sultan et al., 2011).”
BackgroundSelf-citationAccelerated neurodegeneration through chaperone-mediated oligomerization of tau
Blair, L. J., Nordhues, B. A., Hill, S. E., Scaglione, K. M., O’Leary, J. C., Fontaine, S. N., Breydo, L., Zhang, B., Li, P., Wang, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69003 · Cited by 322
Self-citationConformational change as one of the earliest alterations of tau in Alzheimer's disease
Weaver, C. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00157-3 · Cited by 310
Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H., & Duff, K. E. (2012) · Autophagy · doi:10.4161/auto.19048 · Cited by 297
Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278
Self-citationViolet, M., Delattre, L., Tardivel, M., Sultan, A., Chauderlier, A., Caillierez, R., Talahari, S., Nesslany, F., Lefebvre, B., Bonnefoy, E., et al. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00084 · Cited by 251
Self-citationMurakami, K., Murata, N., Noda, Y., Tahara, S., Kaneko, T., Kinoshita, N., Hatsuta, H., Murayama, S., Barnham, K. J., Irie, K., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.279208 · Cited by 241
Methylene Blue Inhibits Amyloid Aβ Oligomerization by Promoting Fibrillization
Necula, M., Breydo, L., Milton, S., Kayed, R., van der Veer, W. E., Tone, P., & Glabe, C. G. (2007) · Biochemistry · doi:10.1021/bi700411k · Cited by 213
Self-citationTau Oligomers Impair Artificial Membrane Integrity and Cellular Viability
Flach, K., Hilbrich, I., Schiffmann, A., Gärtner, U., Krüger, M., Leonhardt, M., Waschipky, H., Wick, L., Arendt, T., & Holzer, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.396176 · Cited by 188 · cited 1×
“The prefibrillar oligomers observed at early stages of AD pathology, rather than larger aggregates, have emerged as the deleterious forms of Tau (Patterson et al., 2011; Lasagna-Reeves et al., 2011; Flach et al., 2012; Mufson et al., 2013).”
BackgroundTau protein binds to pericentromeric DNA: a putative role for nuclear tau in nucleolar organization
Sjöberg, M. K., Shestakova, E., Mansuroglu, Z., Maccioni, R. B., & Bonnefoy, E. (2006) · Journal of Cell Science · doi:10.1242/jcs.02907 · Cited by 166
Self-citationAminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation
Crowe, A., James, M. J., Lee, V. M.-Y., Smith, A. B., Trojanowski, J. Q., Ballatore, C., & Brunden, K. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.436006 · Cited by 143
Wei, Y., Qu, M.-H., Wang, X.-S., Chen, L., Wang, D.-L., Liu, Y., Hua, Q., & He, R.-Q. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002600 · Cited by 129
Galas, M.-C., Dourlen, P., Bégard, S., Ando, K., Blum, D., Hamdane, M., & Buée, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601849200 · Cited by 97
Effect of Phosphorylation and Aggregation on Tau Binding to Dna
Hua, Q., & He, R.-Q. (2002) · Protein & Peptide Letters · doi:10.2174/0929866023408652 · Cited by 53
Research works printed but not linked: 35
- Akoury, 2013, Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation, Angew. Chem. Int. Ed. Engl., 52, 3511, 10.1002/anie.201208290 · DOI · Paper page
- Baddeley, 2015, Complex disposition of methylthioninium redox forms determines efficacy in Tau aggregation inhibitor therapy for Alzheimer's disease, J. Pharmacol. Exp. Ther., 352, 110, 10.1124/jpet.114.219352 · DOI
- Borgesius, 2011, Accelerated age-related cognitive decline and neurodegeneration, caused by deficient DNA repair, J. Neurosci., 31, 12543, 10.1523/JNEUROSCI.1589-11.2011 · DOI · Paper page
- Bradley-Whitman, 2014, Nucleic acid oxidation: an early feature of Alzheimer's disease, J. Neurochem., 128, 294, 10.1111/jnc.12444 · DOI · Paper page
- Camero, 2013, Tau protein provides DNA with thermodynamic and structural features which are similar to those found in histone–DNA complex, J. Alzheimers Dis., 39, 649, 10.3233/JAD-131415 · DOI · Paper page
- Cooper-Knock, 2012, Gene expression profiling in human neurodegenerative disease, Nat. Rev. Neurol., 8, 518, 10.1038/nrneurol.2012.156 · DOI · Paper page
- Deiana, 2009, Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine, Psychopharmacology, 202, 53, 10.1007/s00213-008-1394-2 · DOI
- Fabiszewski, 1990, Effect of antibiotic treatment on outcome of fevers in institutionalized Alzheimer patients, JAMA, 263, 3168, 10.1001/jama.1990.03440230064034 · DOI · Paper page
- Gerson, 2014, Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species, ACS Chem. Neurosci., 5, 752, 10.1021/cn500143n · DOI · Paper page
- Guerrero-Muñoz, 2014, Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins, Biochem. Pharmacol., 88, 468, 10.1016/j.bcp.2013.12.023 · DOI
- Hawkins, 2013, Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between TBI and sporadic tauopathies, J. Biol. Chem., 288, 17042, 10.1074/jbc.M113.472746 · DOI · Paper page
- Hikosou, 2007, Effect of DNA on filament formation of tau microtubule-binding domain: structural dependence of DNA, Chem. Pharm. Bull., 55, 1030, 10.1248/cpb.55.1030 · DOI
- Hosokawa, 2012, Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice, PLoS One, 7, 10.1371/journal.pone.0052389 · DOI · Paper page
- Jiang, 2013, Hyperthermia impaired human visual short-term memory: an fMRI study, Int. J. Hyperth., 29, 219, 10.3109/02656736.2013.786141 · DOI
- Lu, 2013, Hyperphosphorylation results in tau dysfunction in DNA folding and protection, J. Alzheimers Dis., 37, 551, 10.3233/JAD-130602 · DOI · Paper page
- Moreira, 2008, Nucleic acid oxidation in Alzheimer disease, Free Radic. Biol. Med., 44, 1493, 10.1016/j.freeradbiomed.2008.01.002 · DOI · Paper page
- Mufson, 2013, Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's Disease, Neurodegener. Dis., 13, 151, 10.1159/000353687 · DOI · Paper page
- Nunomura, 2012, The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons, J. Neuropathol. Exp. Neurol., 71, 233, 10.1097/NEN.0b013e318248e614 · DOI · Paper page
- O'Leary, 2010, Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden, Mol. Neurodegener., 5, 45, 10.1186/1750-1326-5-45 · DOI · Paper page
- Patterson, 2011, Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease, J. Biol. Chem., 286, 23063, 10.1074/jbc.M111.237974 · DOI · Paper page
- Racinais, 2008, Hyperthermia impairs short-term memory and peripheral motor drive transmission, J. Physiol., 586, 4751, 10.1113/jphysiol.2008.157420 · DOI · Paper page
- Reynolds, 2005, Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease, Biochemistry, 44, 1690, 10.1021/bi047982v · DOI · Paper page
- Rojas, 2012, Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue, Prog. Neurobiol., 96, 32, 10.1016/j.pneurobio.2011.10.007 · DOI · Paper page
- Schindowski, 2006, Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits, Am. J. Pathol., 169, 599, 10.2353/ajpath.2006.060002 · DOI · Paper page
- Spires-Jones, 2014, Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy, Neurosci. Lett., 562, 63, 10.1016/j.neulet.2014.01.013 · DOI · Paper page
- Stack, 2014, Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity, Hum. Mol. Genet., 23, 3716, 10.1093/hmg/ddu080 · DOI · Paper page
- Sutherland, 2013, Oxidative stress in Alzheimer's disease: primary villain or physiological by-product?, Redox Rep., 18, 134, 10.1179/1351000213Y.0000000052 · DOI · Paper page
- Tai, 2012, The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin–proteasome system, Am. J. Pathol., 181, 1426, 10.1016/j.ajpath.2012.06.033 · DOI · Paper page
- Takeda, 2004, Heme catabolism and heme oxygenase in neurodegenerative disease, Antioxid. Redox Signal., 6, 888
- Tepper, 2014, Oligomer formation of tau hyperphosphorylated in cells, J. Biol. Chem., 289, 34389, 10.1074/jbc.M114.611368 · DOI · Paper page
- Van der Jeugd, 2013, Progressive age-related cognitive decline in tau mice, J. Alzheimers Dis., 37, 777, 10.3233/JAD-130110 · DOI · Paper page
- Vanhelmont, 2010, Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast, FEMS Yeast Res., 10, 992, 10.1111/j.1567-1364.2010.00662.x · DOI
- Ward, 2013, TOC1: characterization of a selective oligomeric tau antibody, J. Alzheimers Dis., 37, 593, 10.3233/JAD-131235 · DOI · Paper page
- Zekanowski, 2009, Aneuploidy, chromosomal missegregation, and cell cycle reentry in Alzheimer's disease, Acta Neurobiol. Exp. (Wars), 69, 232, 10.55782/ane-2009-1748 · DOI · Paper page
- Zheng-Fischhöfer, 1998, Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation, Eur. J. Biochem., 252, 542, 10.1046/j.1432-1327.1998.2520542.x · DOI · Paper page
Cited by
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?
Laurent, C., Buée, L., & Blum, D. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.003 · Cited by 348
“[11] Violet M, Chauderlier A, Delattre L, Tardivel M, Chouala MS, Sultan A, et al.”
BackgroundSelf-citationFrom the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy
Colin, M., Dujardin, S., Schraen-Maschke, S., Meno-Tetang, G., Duyckaerts, C., Courade, J.-P., & Buée, L. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02087-9 · Cited by 187
Self-citationMansuroglu, Z., Benhelli-Mokrani, H., Marcato, V., Sultan, A., Violet, M., Chauderlier, A., Delattre, L., Loyens, A., Talahari, S., Bégard, S., et al. (2016) · Scientific Reports · doi:10.1038/srep33047 · Cited by 146
Self-citationGenome instability in Alzheimer disease
Hou, Y., Song, H., Croteau, D. L., Akbari, M., & Bohr, V. A. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.04.005 · Cited by 120
Metadata
- Authors
- Violet, M., Chauderlier, A., Delattre, L., Tardivel, M., Chouala, M. S., Sultan, A., Marciniak, E., Humez, S., Binder, L., Kayed, R., Lefebvre, B., Bonnefoy, E., Buée, L., & Galas, M.-C.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 82
- Pages
- 540-551
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2214399926
- Cited by
- 66
- References
- 18
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Agence Nationale de la Recherche
- LabEx
- DISTALZ
- INSERM
- LMCU
- Région Nord/Pas-de-Calais
- FEDER
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.